TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03226275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
Study: NCT03991104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 capsule
Description: Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (IMRT)
Description: The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
Study: NCT02027623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor skill training
Description: The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength and flexibility exercise
Description: Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
Study: NCT02303691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Training
Description: A control version of computerized attention training.
Study: NCT04432246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: 50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
Study: NCT04553198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward Locomotion Treadmill Training (BLTT)
Description: 9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Backward Locomotion Treadmill Training (BLTT)
Description: 9-training sessions of reverse treadmill training (no bodyweight support)over three weeks.
Study: NCT01014260

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
Study: NCT00562211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LidoDyn
Description: Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA creme
Description: Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
Study: NCT03143816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technosphere insulin
Description: This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
Study: NCT00511472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose \[TD\] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LANTUS insulin
Description: LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LANTUS insulin
Description: LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
Study: NCT02687022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peramis aberrometry
Description: A non-invasive photographic scan sequence acquired in under 10 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peramis aberrometry
Description: A non-invasive photographic scan sequence acquired in under 10 seconds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iDesign aberrometry
Description: A non-invasive photographic scan sequence acquired in under 10 seconds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iDesign aberrometry
Description: A non-invasive photographic scan sequence acquired in under 10 seconds
Study: NCT03682549

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral microbiome analysis
Description: Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral microbiome analysis
Description: Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral microbiome analysis
Description: Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
Study: NCT02308020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT02146456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study: NCT05889481

Intervention type: GENETIC
Intervention: cytogenetic analysis on tumour tissue
Description: Array-CGH methods on oligonucleotide platforms from Agilent Technologies were used. Tumour DNA from MU samples was extracted using the Gentra Pure Gene commercial kit (QIAGEN), as per clinical practice. Once extracted, the quantity and purity of the DNA obtained were evaluated. All samples deemed suitable for quality were processed following the protocol indicated by Agilent Technologies. The data obtained were analysed using Cytogenomics software. These analyses will allow a genotypic characterisation of the tumour to be obtained.

Intervention type: GENETIC
Intervention: cytogenetic analysis on tumour tissue
Description: Array-CGH methods on oligonucleotide platforms from Agilent Technologies were used. Tumour DNA from MU samples was extracted using the Gentra Pure Gene commercial kit (QIAGEN), as per clinical practice. Once extracted, the quantity and purity of the DNA obtained were evaluated. All samples deemed suitable for quality were processed following the protocol indicated by Agilent Technologies. The data obtained were analysed using Cytogenomics software. These analyses will allow a genotypic characterisation of the tumour to be obtained.

Intervention type: BIOLOGICAL
Intervention: Digital Pathology
Description: Digital Pathology is an emerging discipline that enables quantitative analysis of digital images using highly standardised approaches. It will allow quantitative measurements of the interactions between immune cells and characterise their relative spatial distribution. In addition, it will be able to generate further information that will allow in-depth study of the tumour microenvironment of uveal melanoma

Intervention type: BIOLOGICAL
Intervention: Digital Pathology
Description: Digital Pathology is an emerging discipline that enables quantitative analysis of digital images using highly standardised approaches. It will allow quantitative measurements of the interactions between immune cells and characterise their relative spatial distribution. In addition, it will be able to generate further information that will allow in-depth study of the tumour microenvironment of uveal melanoma
Study: NCT01432717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-536
Description: Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
Study: NCT04388774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single 40-minute intravenous infusion
Study: NCT03027492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten free diet
Description: The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
Study: NCT01190982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEP-ETU
Description: 275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
Study: NCT02483182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEP-3 ointment 1.0%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir cream 5%
Study: NCT04305080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anodic oxidation
Description: Abutments will undergo anodic oxidation process after etching with Hydrofluoric acid \& Nitric acid mixture for 10 minutes for debridement in a bath of distilled water with citric acid for 5 minutes to turn the abutment collar into pink color. The stainless steel plate will be connected to the cathode (-) and titanium abutments will be connected to the anode (+) end of the DC Power Supply. After then abutments will be left in distilled water for 10 minutes and sterilized before insertion in patient mouth.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Untreated abutment
Description: Abutment will be left untreated with its gray color.
Study: NCT00343252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 20 ug/day, subcutaneous, 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risedronate
Description: 35 mg/once weekly, oral, 18 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: once weekly, oral, 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: daily, subcutaneous, 18 months
Study: NCT00947674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellsorba EX
Description: conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cellsorba EX
Description: conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
Study: NCT03313921

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Online Manifest Refraction
Description: The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.~The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000.
Study: NCT02414581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine 0.12%/Ethyl alcohol 7%
Description: Mouth rinses with chlorhexidine 0.12%-based solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethyl Alcohol 7%
Description: Mouth rinses with Ethyl Alcohol 7%-based solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 2%/Ethyl alcohol 7%
Description: Mouth rinses with chlorhexidine 2%-based solution
Study: NCT03742167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
Study: NCT00988871

Intervention type: DEVICE
Intervention: PICC, CICC
Description: PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
Study: NCT03905954

Intervention type: OTHER
Intervention: Usual care
Description: For this cross sectional survey, participants will be receiving usual care according to there health care systems
Study: NCT02275494

Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Description: Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.

Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Description: Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.

Intervention type: PROCEDURE
Intervention: Total hip arthroplasty
Description: Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
Study: NCT01003990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: Tablets, Oral, 400 mg, once daily, indefinitely

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir
Description: Tablets, Oral, 300/100 mg, once daily, indefinitely

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: Tablets, Oral, 300/200 mg, once daily, indefinitely

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Tablets, Oral, 400/100 mg, twice daily, indefinitely
Study: NCT02178670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSC-DC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSC-DC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSC-DC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CSC-DC
Study: NCT01492465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 876
Description: Ascending single doses of study drug administered SC, with one cohort administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 876
Description: Ascending single doses of study drug administered SC, with one cohort administered IV
Study: NCT01285271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
Study: NCT02919657

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Genepro Protein
Description: weekly blood draws to measure blood protein levels

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: weekly blood draws to measure blood protein levels
Study: NCT04154176

Intervention type: OTHER
Intervention: CAM, Nu-DESC
Description: Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
Study: NCT04470466

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: short pulse and Q-switched ND-YAG laser with topical carbon
Description: application of topical carbon cream, followed by two passes of short pulse 1064 ND-YAG, then one pass of Q-switched 1064 ND-YAG on one side of the face

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fractional CO2 laser
Description: single pass of fractional CO2 laser on the other side of the face
Study: NCT03286322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manuel therapy cervical spine
Description: the manuel therapy in physiotherapy is focused on the cervival spine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: the manuel therapy in physiotherapy is classic and not focused on the cervival spine
Study: NCT01551212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: capsule containing 0.5, 1.0, or 5.0mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: capsule containing 0.5, 1.0, or 5.0mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.